Scar-Improving efficacy of avotermin administered into the Wound margins of skin incisions as evaluated by a randomized, double-Blind, placebo-Controlled, phase II clinical trial

Plastic and Reconstructive Surgery

Volumn 126, Issue 5, 2010, Pages 1604-1615

  Bush, James ^b   Duncan, Jonathan A L ^b   Bond, Jeremy S ^b   Durani, Piyush ^b   So, Karen ^b   Mason, Tracey ^b   O'Kane, Sharon ^b   Ferguson, Mark W J ^a  

^a Renovo   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA3;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECT; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; PAIN ASSESSMENT; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SCAR; SKIN; WOUND HEALING;

ADOLESCENT; ADULT; CICATRIX; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PAIN MEASUREMENT; SKIN; TRANSFORMING GROWTH FACTOR BETA3; WOUND HEALING; YOUNG ADULT;

EID: 78650078703     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181ef8e66     Document Type: Article

References (14)

1. Young VL, Hutchison J. Insights into patient and clinician concerns about scar appearance: Semiquantitative structured surveys. Plast Reconstr Surg. 2009;124:256-265.
2. Bayat A, McGrouther DA, Ferguson MWJ. Skin scarring. BMJ. 2003;326:88-92.
3. Mustoe TA, Cooter RD, Gold M, et al. International clinical recommendations on scar management. Plast Reconstr Surg. 2002;110:560-571.
4. Meier K, Nanney LB. Emerging new drugs for scar reduction. Expert Opin Emerg Drugs 2006;11:39-47.
5. Ferguson MWJ, Whitby DJ, Shah M, Armstrong J, Siebert JW, Longaker MT. Scar formation: The spectral nature of fetal and adult wound repair. Plast Reconstr Surg. 1996;97:854-860.
6. Ferguson MWJ, O'Kane S. Scar-free healing: From embryonic mechanisms to adult therapeutic intervention. Philos Trans R Soc Lond B Biol Sci. 2004;359:839-850.
7. O'Kane S, Ferguson MWJ. Transforming growth factor betas and wound healing. Int J Biochem Cell Biol. 1997;29:63-78.
8. Hsu M, Peled ZM, Chin GS, Liu W, Longaker MT. Ontogeny of expression of transforming growth factor-beta 1 (TGF-beta 1), TGF-beta 3, and TGF-beta receptors I and II in fetal rat fibroblasts and skin. Plast Reconstr Surg. 2001;107:1787-1794. (Pubitemid 32577789)
9. Shah M, Foreman DM, Ferguson MWJ. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGFbeta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995;108(Pt 3):985-1002.
10. Ferguson MWJ, Duncan J, Bond J, et al. Prophylactic administration of avotermin for improvement of skin scarring: Three double-blind, placebo-controlled, phase I/II studies. Lancet 2009;373:1264-1274.
11. Duncan JA, Bond JS, Mason T, et al. Visual analogue scale scoring and ranking: A suitable and sensitive method for assessing scar quality? Plast Reconstr Surg. 2006;118:909-918.
12. Cook JL, Dzubow LM. Aging of the skin: Implications for cutaneous surgery. Arch Dermatol. 1997;133:1273-1277.
13. Gangemi EN, Gregori D, Berchialla P, et al. Epidemiology and risk factors for pathologic scarring after burn wounds. Arch Facial Plast Surg. 2008;10:93-102.
14. Ashcroft GS, Horan MA, Ferguson MWJ. Aging is associated with reduced deposition of specific extracellular matrix components, an upregulation of angiogenesis, and an altered inflammatory response in a murine incisional wound healing model. J Invest Dermatol. 1997;108:430-437.